Ramucirumab Plus TAS-102 Fails to Improve OS in Heavily Pretreated mCRC - OncLive
The phase 3 IKF-AIO-RAMTAS trial found no significant OS improvement with ramucirumab + TAS-102 vs TAS-102 alone in heavily pretreated mCRC patients, though benefits were seen in female patients and those with left-sided tumors. The combination showed improved PFS and DCR but increased hematotoxicity and dose reductions.
Related Clinical Trials
Reference News
Ramucirumab Plus TAS-102 Fails to Improve OS in Heavily Pretreated mCRC - OncLive
The phase 3 IKF-AIO-RAMTAS trial found no significant OS improvement with ramucirumab + TAS-102 vs TAS-102 alone in heavily pretreated mCRC patients, though benefits were seen in female patients and those with left-sided tumors. The combination showed improved PFS and DCR but increased hematotoxicity and dose reductions.